Loading clinical trials...
Loading clinical trials...
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Telik
NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more
NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, and more
NCT04895709 · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, and more
NCT07213804 · Ovarian Neoplasms, Fallopian Tube Neoplasms, and more
NCT06051695 · Solid Tumor, Adult, Colorectal Cancer, and more
Little Rock Hematology Oncology Associates
Little Rock, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Southern California Permanente Medical Group
Baldwin Park, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions